Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia

Neurobiology of Disease

Volumn 15, Issue 3, 2004, Pages 618-629

  Miller, Christine L ^a   Llenos, Ida C ^b   Dulay, Jeanette R ^b   Barillo, Meliza M ^b   Yolken, Robert H ^a   Weis, Serge ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Human; Immunohistochemistry; INDO; Indoleamine dioxygenase; mRNA; Protein; Psychosis; RT PCR; TDO2; Tryptophan pyrrolase

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MESSENGER RNA; TRYPTOPHAN 2,3 DIOXYGENASE;

ARTICLE; ASTROCYTE; CADAVER; CELL LABELING; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LATENT SCHIZOPHRENIA; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIFORM DISORDER; WHITE MATTER;

ADULT; AGED; BLOTTING, WESTERN; DIOXYGENASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL LOBE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; OXYGENASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA; SMOKING; TRYPTOPHAN OXYGENASE;

EID: 1842419381     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.12.015     Document Type: Article

References (68)

1. Ackner B., Cooper J.E., Gray C.H., Kelly M. Acute porphyria: a neuropsychiatric and biochemical study. J. Psychosom. Res. 6:1962;1-24.
2. Arnold S.E., Trojanowski J.Q. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol. (Berlin). 92(3):1996;217-231.
3. Artavanis-Tsakonas K., Riley E.M. Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 169(6):2002;2956-2963.
4. Badawy A.A., Evans M. The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate). Biochem. J. 156(2):1976;381-390.
5. Bodaghi B., Goureau O., Zipeto D., Laurent L., Virelizier J.L., Michelson S. Role of IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162(2):1999;957-964.
6. Brown R.R., Ozaki Y., Datta S.P., Borden E.C., Sondel P.M., Malone D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294:1991;425-435.
7. Butler T., Ho M., Acharya G., Tiwari M., Gallati H. Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob. Agents Chemother. 37(11):1993;2418-2421.
8. Cho-chung Y.S., Pitot H.C. Feedback control of rat liver tryptophan pyrrolase. J. Biol. Chem. 242(6):1967;1192-1198.
9. Cho-chung Y.S., Pitot H.C. Regulatory effects of nicotinamide on tryptophan pyrrolase synthesis in rat liver in vivo. Eur. J. Biochem. 3(4):1968;401-406.
10. Comings D.E., Muhleman D., Dietz G., Sherman M., Forest G.L. Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat. Genomics. 29(2):1995;390-396.
11. Daubener W., Spors B., Hucke C., Adam R., Stins M., Kim K.S., Schroten H. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect. Immun. 69(10):2001;6527-6531.
12. Erhardt S., Oberg H., Engberg G. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons. Naunyn-Schmiedebergs Arch. Pharmacol. 363(1):2001;21-27.
13. Foster A.C., Vezzani A., French E.D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48(3):1984;273-278.
14. Gal E.M. Cerebral tryptophan-2,3-dioxygenase (pyrrolase) and its induction in rat brain. J. Neurochem. 22(5):1974;861-863.
15. Grant R.S., Naif H., Thuruthyil S.J., Nasr N., Littlejohn T., Takikawa O., Kapoor V. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by HIV-1. Redox Rep. 5(2-3):2000;105-107.
16. Green A.R., Curzon G. Decrease of 5-hyroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature. 220:1968;1095-1097.
17. Guidetti P., Schwarcz R. 3-Hyroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11(11):1999;3857-3863.
18. Guidetti P., Reddy P., Tagle D.A., Schwarcz R. Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model. Neurosci. Lett. 283(3):2000;233-235.
19. Guillemin, G.J., Kerr, S.J. Smythe, G.A., Armati, P.J., Brew, B.J., 1999. Kynurenine pathway metabolism in human astrocytes. In: Heuther, G., Kochen, W., Simat, T.J., Steinhart, H. (Eds.). Tryptophan, Serotonin and Melatonin: Basic Aspects and Applications. Kluwer Academic/Plenum Publishers, New York, pp. 125-131.
20. Guillemin G.J., Kerr S.J., Smythe B.A., Smith D.G., Kapoor V., Armati P.J., Croitoru J., Brew B.J. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78:2001;842-853.
21. Haber R., Bessette D., Hulihan-Giblin B., Durcan M.J., Goldman D. Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J. Neurochem. 60(3):1993;1159-1162.
22. Hankes L.V., Leklem J.E., Brown R.R., Mekel R.C.P.M. Tryptophan metabolism in patients with pellagra: the problem of vitamin B6 activity and feedback control of tryptophan pyrrolase enzyme. Am. J. Clin. Nutr. 24(6):1971;730-739.
23. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. 79:1976;13-21.
24. Heyes M.P., Chen C.Y., Major E.O., Saito K. Different kyurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J. 326:1997;351-356.
25. Hilmas C., Pereira E.F.R., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21(19):2001;7463-7473.
26. Horrobin D.F. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Orthomol. Psychiatry. 9:1980;33-34.
27. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
28. Ivarsson, K., Weijdegard, B., 1998. Evaluation of the effects of DNase treatment on signal specificity in RT-PCR and in situ RT-PCR. Biotechniques 25 (4), 630-632, 634, 636.
29. Johnston N.L., Cervenak J., Shore A.D., Torrey E.F., Yolken R.H., Cerevnak J. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR, Stanley Neuropathology Consortium. J. Neurosci. Methods. 77(1):1997;83-92.
30. Kishore N., Tewari Y.B., Akers D.L., Goldberg R.N., Miles E.W. A thermodynamic investigation of reactions catalyzed by tryptophan synthase. Biophys. Chem. 73(3):1998;265-280.
31. Knox W.E., Mehler A.H. The conversion of tryptophan to kynurenine in the liver. J. Biol. Chem. 187:1950;419-430.
32. Maezono K., Tashiro K., Nakamura T. Deduced primary structure of rat tryptophan-2,3-dioxygenase. Biochem. Biophys. Res. Commun. 170(1):1990;176-181.
33. Magni G., Amici A., Emanuelli M., Raffaelli N. Enzymology of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73:1999;135-182.
34. McCoy J.M., Wicks J.R., Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110(5):2002;651-658.
35. Miller C.L., Yolken R.H. Methods to optimize the generation of cDNA from postmortem human brain tissue. Brain Res. Protoc. 10(3):2003;156-167.
36. Mills C.M., Hill S.A., Marks R. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol. 133(7):1997;823-825.
37. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375(1-3):1999;87-100.
38. Nagineni C.N., Pardhasaradhi K., Martins M.C., Detrick B., Hooks J.J. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect. Immun. 64(10):1996;4188-4196.
39. Oken R.J., Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 25(4):1999;625-638.
40. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283(3):1997;1264-1275.
41. Poillon W.N., Maeno H., Koike K., Feigelson P. Tryptophan oxygenase of Pseudomonas acidovorans. Purification, composition, and subunit structure. J. Biol. Chem. 244(13):1969;3447-3456.
42. Rapoport M.I., Beisel W.R. Studies of tryptophan metabolism in experimental animals and man during infectious illness. Am. J. Clin. Nutr. 24(7):1971;807-814.
43. Reinhard J.F. Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid. Neurochem. Res. 23(5):1998;661-665.
44. Ren S., Correia M.A. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase? Arch. Biochem. Biophys. 377(1):2000;195-203.
45. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132:2000;365-386.
46. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry. 29(8):1991;834-836.
47. Saareks V., Mucha I., Sievi E., Ruitta A. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol. Toxicol. 84(6):1999;274-280.
48. Sainio E.L. The role of adrenal hormones in the activation of tryptophan 2,3-dioxygenase by nicotinic acid in rat liver. Methods Find. Exp. Clin. Pharmacol. 19(7):1997;465-470.
49. Sanni L.A., Thomas S.R., Tattam B.N., Moore D.E., Chaudhri G., Stocker R., Hunt N.H. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am. J. Pathol. 152(2):1998;611-619.
50. Scherer B., Kramer W. Influence of niacinamide administration on brain 5-HT and a possible mode of action. Life Sci. 11(4):1972;189-195.
51. Schutz G., Feigelson P. Purification and properties of rat liver tryptophan oxygenase. J. Biol. Chem. 247(17):1972;5327-5332.
52. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects and clinical opportunities. J. Pharmacol. Exp. Ther. 303(1):2002;1-10.
53. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry. 50(7):2001;521-530.
54. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 49(1-2):2001;1-52.
55. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45(3):1993;309-379.
56. Tishler P.V., Woodward B., O'Connor J., Holbrook D.A., Seidman L.J., Hallett M. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am. J. Psychiatry. 142(12):1985;1430-1436.
57. Torrey E.F. Surviving Schizophrenia: A Family Manual. Second ed. 1988;188 Harper Collins, New York.
58. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr. Res. 44(2):2000;151-155.
59. Uitenbroek D.G. SISA Binomial. 1997;D.G. Uitenbroek, Southampton.
60. Vincendeau P., Lesthelle S., Bertazzo A., Okomo-Assoumou M.C., Allegri G., Costa C.V. Importance of L-tryptophan metabolism in trypanosomiasis. Adv. Exp. Med. Biol. 467:1999;525-531.
61. Waldo M.C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40(1):1999;49-53.
62. Ward P.E., Sutherland J., Glen E.M.T., Glen A.I.M. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29(3):1998;269-274.
63. Weis S., Haug H., Budka H. Astroglial changes in the cerebral cortex of AIDS brains. A morphometric and immunohistochemical investigation. Neuropathol. Appl. Neurobiol. 19:1993;329-335.
64. Wetterberg L. A Neuropsychiatric and Genetical Investigation of Acute Intermittent Porphyria. 1967;Scandanavian University Books, Stockholm.
65. Wetterberg L. Glucose effect on tryptophan oxygenase and tyrosine aminotransferase induction after allylisopropylacetamide-induced porphyria in the rat. Biochem. Pharmacol. 19(11):1970;2833-2838.
66. Yap G.S., Sher A. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-γ- and tumor necrosis factor (TNF)-α-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J. Exp. Med. 189(7):1999;1083-1091.
67. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8(1):1995;131-145.
68. Zerez C.R., Roth E.F., Schulman S., Tanaka K.R. Increased nicotinamide adenine dinucleotide content and synthesis in Plasmodium falciparum-infected human erythrocytes. Blood. 75(8):1990;1705-1710.